Everolimus

Proven oncology and transplant drug. The resTORbio trial showed improved immune function in elderly at low doses, but the company's clinical programs were ultimately discontinued.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Robust oncology data for RCC, breast cancer (with exemestane), and TSC. A low-dose trial in elderly volunteers showed improved influenza vaccine response and reduced infections, suggesting immune rejuvenation. resTORbio's Phase III PROTECTOR trial in respiratory infections failed, dampening clinical longevity enthusiasm.

• FDA-approved for multiple cancers and transplant rejection
• Demonstrated immune function improvement in elderly at low doses
• Well-characterized pharmacology as an mTOR inhibitor

Oncology: 10 mg/day. Transplant: titrated to trough levels. Longevity research used 0.5 mg/day or 5 mg/week.

• Stomatitis
• Infections
• Hyperglycemia
• Dyslipidemia
• Pneumonitis

Immunosuppression increases infection risk. Stomatitis (mouth sores) is very common. Metabolic effects include hyperglycemia and dyslipidemia. Interstitial lung disease risk.

Longevity applications hit a setback with the failed PROTECTOR trial. Low-dose immune benefits from a single positive study need replication.

• Longevity50
• Immunity40